Percheron Therapeutics (AU:PER) has released an update.
Percheron Therapeutics has announced the termination of its phase IIb trial of avicursen for Duchenne muscular dystrophy after the drug failed to meet its primary endpoint. Despite demonstrating a favorable safety profile, the company did not observe any significant efficacy benefits. Investors can expect further strategic updates in 2025 as Percheron re-evaluates its pipeline.
For further insights into AU:PER stock, check out TipRanks’ Stock Analysis page.